Search Results

Susan G. Komen®, the world’s leading breast cancer organization, announced $10.05 million in research grants that aim to improve patient lives through better treatments for metastatic disease and advancements in precision medicine.

Susan G. Komen®, the world’s leading breast cancer organization, announced four new global leaders to serve on its Board of Directors.

Susan G. Komen®, the world’s leading breast cancer organization and Walgreens announced another milestone in the transformative five-year collaboration that has not only propelled groundbreaking research in breast cancer but has also significantly expanded access to essential breast health and breast cancer services, support and resources.

Susan G. Komen®, the world’s leading breast cancer organization, has launched the Stand for H.E.R. – A Health Equity Revolution Breast Cancer Impact Report.

Analysts at Leerink Partners said in a Monday note that DESTINY-Breast09’s findings “could support an approval” for Enhertu in first-line HER2+ metastatic breast cancer.

Susan G. Komen ® , the world’s leading breast cancer organization, today announced the awarding of 49 new grants to researchers at 28 leading institutions in the U.S.

Combining Trodelvy with Keytruda and pushing it into the frontline setting could “potentially double” the ADC’s market in metastatic triple-negative breast cancer, according to analysts at Truist Securities.